Recap: Journey Medical Q3 Earnings
Portfolio Pulse from Benzinga Insights
Journey Medical (NASDAQ:DERM) reported Q3 earnings, beating estimated earnings by 760.0% with an EPS of $0.99 against an estimate of $-0.15. Revenue was up $18.42 million from the same period last year. Last quarter, the company beat EPS by $0.29, which led to a 1.67% increase in the share price the next day.
November 07, 2023 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Journey Medical's Q3 earnings beat estimates significantly, which could lead to a positive impact on its stock price, as seen in the previous quarter.
Journey Medical reported a significant beat on its Q3 earnings, exceeding estimates by 760.0%. This positive earnings report could lead to an increase in the company's stock price, as investors often react positively to earnings beats. This is further supported by the company's past performance, where a beat on EPS in the previous quarter led to a 1.67% increase in the share price the next day.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100